Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin
16 nov. 2020 08h05 HE
|
Aeterna Zentaris Inc
- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-P02...